GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » OptimizeRx Corp (NAS:OPRX) » Definitions » Cyclically Adjusted Price-to-FCF

OptimizeRx (OptimizeRx) Cyclically Adjusted Price-to-FCF : (As of May. 14, 2024)


View and export this data going back to 2009. Start your Free Trial

What is OptimizeRx Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


OptimizeRx Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for OptimizeRx's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OptimizeRx Cyclically Adjusted Price-to-FCF Chart

OptimizeRx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

OptimizeRx Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of OptimizeRx's Cyclically Adjusted Price-to-FCF

For the Health Information Services subindustry, OptimizeRx's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OptimizeRx's Cyclically Adjusted Price-to-FCF Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, OptimizeRx's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where OptimizeRx's Cyclically Adjusted Price-to-FCF falls into.



OptimizeRx Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

OptimizeRx's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, OptimizeRx's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.308/129.4194*129.4194
=-0.308

Current CPI (Dec. 2023) = 129.4194.

OptimizeRx Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 0.021 99.695 0.027
201406 -0.062 100.560 -0.080
201409 -0.037 100.428 -0.048
201412 0.021 99.070 0.027
201503 0.008 99.621 0.010
201506 0.018 100.684 0.023
201509 0.022 100.392 0.028
201512 0.003 99.792 0.004
201603 -0.031 100.470 -0.040
201606 0.002 101.688 0.003
201609 0.001 101.861 0.001
201612 -0.053 101.863 -0.067
201703 -0.032 102.862 -0.040
201706 -0.050 103.349 -0.063
201709 -0.085 104.136 -0.106
201712 0.011 104.011 0.014
201803 -0.084 105.290 -0.103
201806 -0.039 106.317 -0.047
201809 0.083 106.507 0.101
201812 0.076 105.998 0.093
201903 0.067 107.251 0.081
201906 -0.081 108.070 -0.097
201909 -0.069 108.329 -0.082
201912 -0.139 108.420 -0.166
202003 -0.257 108.902 -0.305
202006 0.008 108.767 0.010
202009 -0.009 109.815 -0.011
202012 -0.177 109.897 -0.208
202103 0.098 111.754 0.113
202106 0.003 114.631 0.003
202109 0.002 115.734 0.002
202112 -0.073 117.630 -0.080
202203 0.225 121.301 0.240
202206 0.010 125.017 0.010
202209 0.191 125.227 0.197
202212 0.162 125.222 0.167
202303 -0.018 127.348 -0.018
202306 -0.204 128.729 -0.205
202309 0.069 129.860 0.069
202312 -0.308 129.419 -0.308

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


OptimizeRx  (NAS:OPRX) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


OptimizeRx Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of OptimizeRx's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


OptimizeRx (OptimizeRx) Business Description

Traded in Other Exchanges
N/A
Address
400 Water Street, Suite 200, Rochester, MI, USA, 48307
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
Executives
Marion Odence-ford officer: General Counsel and CCO 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Theresa Greco officer: Chief Commercial Officer 260 CHARLES STREET, SUITE 302, WALTHAM MA 02153
Doug Besch officer: Chief Product Officer 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
William J Febbo officer: Chief Executive Officer 600 CALIFORNIA ST., 9TH FLOOR, SAN FRANCISCO CA 94108
James Paul Lang director C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Stephen L Silvestro officer: Chief Commercial Officer 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Ellen O'connor Vos director C/O NTELOS HOLDINGS CORP., 1154 SHENANDOAH VILLAGE DRIVE, WAYNESBORO VA 22980
Edward Stelmakh officer: COO and CFO 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Miriam J Paramore officer: President 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Patrick D Spangler director, officer: SVP of Product & Strategy 14405 21ST AVENUE NORTH, MINNEAPOLIS MN 55447
Douglas P Baker officer: Chief Financial Officer 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Todd Inman officer: Chief Technology Officer 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Gregory D Wasson director 200 WILMOT ROAD, DEERFIELD IL 60015
Gus D Halas director 38 PHEASANT RUN PLACE, DANVILLE CA 94506
Awm Investment Company, Inc. 10 percent owner 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022